NCT07446257
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
- University of Texas Southwestern Medical Center Dallas, Texas, United States
Clinical trial condition
Resectable Hepatocellular Carcinoma
Explore clinical trials studying Resectable Hepatocellular Carcinoma. Study availability and eligibility vary by location and protocol.
15 public trials
3 recruiting studies
Resectable Hepatocellular Carcinoma trial results
NCT07018947
- Conditions
- Resectable Hepatocellular Carcinoma
- Locations
-
- Hospital Universitari Germans Trias i Pujol Badalona, Barcelona, Spain
- Hospital Universitari de Bellvitge Barcelona, Spain
- Hospital Universitari Vall d'Hebron Barcelona, Spain
- Hospital Universitario Marqués de Valdecilla Santander, Cantabria, Spain
NCT06569498
- Conditions
- Resectable Hepatocellular Carcinoma
- Locations
-
- Fujian provincial hospital Fuzhou, Fujian, China
- First Affiliated Hospital of Fujian Medical University Fuzhou, Fujian, China
- Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou, Fujian, China
- Zhongshan Hospital of Xiamen University Xiamen, Fujian, China
Not yet recruiting
Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)
NCT07714317
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
Not specified
Active, not recruiting
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
NCT04721132
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +13 more
- Locations
-
- Houston Methodist Hospital Houston, Texas, United States
- M D Anderson Cancer Center Houston, Texas, United States
Active, not recruiting
SIRT With Tremelimumab and Durvalumab for Resectable HCC
NCT05701488
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +11 more
- Locations
-
- Cedars-Sinai Medical Center Los Angeles, California, United States
- Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
Active, not recruiting
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
NCT02379377
- Conditions
- Adenocarcinoma, Adult Hepatocellular Carcinoma, Benign Liver Tumor, +13 more
- Locations
-
- MD Anderson Cancer Center Houston, Texas, United States
Active, not recruiting
Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer
NCT04856046
- Conditions
- Resectable Hepatocellular Carcinoma
- Locations
-
- Mayo Clinic in Rochester Rochester, Minnesota, United States
Active, not recruiting
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
NCT04857684
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
- Locations
-
- Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
Active, not recruiting
Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma
NCT06524466
- Conditions
- CNLC IIIA Stage, Macrovascular Invasion, Resectable Hepatocellular Carcinoma
- Locations
-
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China